Creacion Ventures

Sirius Therapeutics is a biotechnology company specializing in the development of RNA interference (RNAi) therapies. It focuses on treating chronic cardiovascular diseases, providing innovative solutions for both physicians and patients.

Frontera Therapeutics is a company specializing in adeno-associated virus (AAV) gene therapy, dedicated to creating a low-cost and scalable platform for the development and production of high-quality recombinant AAV therapies. The company focuses on commercializing cost-effective gene therapies aimed at treating a range of genetic disorders, including those affecting ophthalmology, liver, metabolic, and neuromuscular diseases. Frontera Therapeutics has established a robust product pipeline that encompasses multiple therapeutic areas, with various candidates at different stages of development. Through its innovative approach, the company aims to improve patient outcomes by making genetic therapies more accessible and affordable in the global market.

MoMa Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company specializes in discovering precision medicines by targeting the molecular machines that are fundamental to human disease. Formerly known as ATPases NewCo, Inc., MoMa Therapeutics utilizes a unique platform that leverages the shared characteristics of ATPase enzymes, including their large-scale conformational changes and energy-driven mechanics. By integrating advances in structural biology and small-molecule drug discovery, MoMa Therapeutics aims to develop therapies targeting this previously challenging class of enzymes, thereby advancing the field of precision medicine.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.

MoMa Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company specializes in discovering precision medicines by targeting the molecular machines that are fundamental to human disease. Formerly known as ATPases NewCo, Inc., MoMa Therapeutics utilizes a unique platform that leverages the shared characteristics of ATPase enzymes, including their large-scale conformational changes and energy-driven mechanics. By integrating advances in structural biology and small-molecule drug discovery, MoMa Therapeutics aims to develop therapies targeting this previously challenging class of enzymes, thereby advancing the field of precision medicine.

Sirius Therapeutics is a biotechnology company specializing in the development of RNA interference (RNAi) therapies. It focuses on treating chronic cardiovascular diseases, providing innovative solutions for both physicians and patients.